Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.

Source: [The Hill](https://thehill.com/opinion/healthcare/6040418-fda-regulatory-delay-regenative-labs/)

Sponsored